Abstract
Tyrosine hydroxylase (TH) is the rate limiting step in the biosynthesis of dopamine and other catecholamines. Differences have been noted in concentration and availability of this enzyme and its cofactors in disease states such as Parkinson’s disease (PD) which are subject to alterations in catecholamines. More evidence suggests in fact that TH may play a direct role in the pathogenesis of PD, especially through oxidative stress and pro-inflammatory mechanisms. Treatment for PD has classically involved maximizing endogenous dopamine by medicinal options that either replace dopamine or augment the dopaminergic pathway. The medications are unfortunately limited, given they are not curative and involve potential short-term and long-term side effects. Gene therapy in PD is a burgeoning field which provides a way to augment dopamine production, and potentially protect the dopaminergic neurons from further degeneration. Given its importance in dopamine catabolism and the possibility that it may contribute to pathogenesis, TH is one target of gene therapy. Further research into the regulatory mechanisms and function of TH are promising in improving gene therapy approaches as well as other treatment modalities.
Keywords: Gene therapy, oxidative stress, Parkinson’s disease, tyrosine hydroxylase.
CNS & Neurological Disorders - Drug Targets
Title:The Function of Tyrosine Hydroxylase in the Normal and Parkinsonian Brain
Volume: 11 Issue: 4
Author(s): Christopher Tolleson and Daniel Claassen
Affiliation:
Keywords: Gene therapy, oxidative stress, Parkinson’s disease, tyrosine hydroxylase.
Abstract: Tyrosine hydroxylase (TH) is the rate limiting step in the biosynthesis of dopamine and other catecholamines. Differences have been noted in concentration and availability of this enzyme and its cofactors in disease states such as Parkinson’s disease (PD) which are subject to alterations in catecholamines. More evidence suggests in fact that TH may play a direct role in the pathogenesis of PD, especially through oxidative stress and pro-inflammatory mechanisms. Treatment for PD has classically involved maximizing endogenous dopamine by medicinal options that either replace dopamine or augment the dopaminergic pathway. The medications are unfortunately limited, given they are not curative and involve potential short-term and long-term side effects. Gene therapy in PD is a burgeoning field which provides a way to augment dopamine production, and potentially protect the dopaminergic neurons from further degeneration. Given its importance in dopamine catabolism and the possibility that it may contribute to pathogenesis, TH is one target of gene therapy. Further research into the regulatory mechanisms and function of TH are promising in improving gene therapy approaches as well as other treatment modalities.
Export Options
About this article
Cite this article as:
Tolleson Christopher and Claassen Daniel, The Function of Tyrosine Hydroxylase in the Normal and Parkinsonian Brain, CNS & Neurological Disorders - Drug Targets 2012; 11 (4) . https://dx.doi.org/10.2174/187152712800792794
DOI https://dx.doi.org/10.2174/187152712800792794 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vasopressin-Receptor Antagonists: A New Class of Agents for the Treatment of Hyponatremia
Endocrine, Metabolic & Immune Disorders - Drug Targets Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens
Current Drug Metabolism Current Aspects of Carbohydrate Structural Bioinformatics
Current Chemical Biology Editorial [Hot Topic: Molecular Pharmacology of the GABAA Receptor (Guest Editor: Gustav Akk)]
Current Neuropharmacology Multiple Hormonal Dysregulation as Determinant of Low Physical Performance and Mobility in Older Persons
Current Pharmaceutical Design The Allosteric Properties of Hemoglobin: Insights from Natural and Site Directed Mutants
Current Protein & Peptide Science Serotonin Involvement in the Basal Ganglia Pathophysiology: Could the 5-HT2C Receptor be a New Target for Therapeutic Strategies?
Current Medicinal Chemistry Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Managed Health Care and Child Mental Health Services: Where Is Horton to Hear the Whos?
Current Pediatric Reviews Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis The Potentials of Selected Therapeutic Targets for Inflammation: A Snapshot
Recent Patents on Inflammation & Allergy Drug Discovery Combating Mosquito-Borne Lymphatic Filariasis with Genomics Technologies: Enabling Novel Drug Discovery for Neglected Tropical Diseases
Current Pharmacogenomics and Personalized Medicine Therapeutics Targeting Nogo-A Hold Promise for Stroke Restoration
CNS & Neurological Disorders - Drug Targets Lifestyle and Health promotional Guidelines in Irritable Bowel Syndrome Patients from the Viewpoint of Persian Medicine
Current Traditional Medicine Flexible Bronchoscopy Biopsy Tools and Techniques to Optimize Diagnostic Yield: A Contemporary Review
Current Respiratory Medicine Reviews Psychedelics as Medicines for Substance Abuse Rehabilitation: Evaluating Treatments with LSD, Peyote, Ibogaine and Ayahuasca
Current Drug Abuse Reviews Obstructive Sleep Apnea and Hypertension: A Bidirectional Causal Relation
Current Respiratory Medicine Reviews Recent Advances in Medicinal Chemistry and Pharmaceutical Technology- Strategies for Drug Delivery to the Brain
Current Topics in Medicinal Chemistry Further Evaluation of Mechanisms Associated with the Antidepressantlike Signature of Scopolamine in Mice
CNS & Neurological Disorders - Drug Targets Dietary Polyphenols for Treatment of Alzheimer’s Disease– Future Research and Development
Current Pharmaceutical Biotechnology